Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and efficacy of ABX464 in moderate to severe active rheumatoid arthritis (Phase 2a follow-up, open-label)
2019-001578-27Phase 2Completed
- Sponsor
- Abivax
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of obefazimod in rheumatoid arthritis (RA), sponsored by Abivax. Primary endpoint: Primary safety endpoint. Started Sep 2019; status: completed.
02
Drugs
obefazimod
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2019-001578-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001578-27.